JP2008515852A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008515852A5 JP2008515852A5 JP2007535159A JP2007535159A JP2008515852A5 JP 2008515852 A5 JP2008515852 A5 JP 2008515852A5 JP 2007535159 A JP2007535159 A JP 2007535159A JP 2007535159 A JP2007535159 A JP 2007535159A JP 2008515852 A5 JP2008515852 A5 JP 2008515852A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- het
- aryl
- group selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 diastereomers Chemical class 0.000 claims 49
- 229910052799 carbon Inorganic materials 0.000 claims 45
- 229910052739 hydrogen Inorganic materials 0.000 claims 41
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 37
- 125000003118 aryl group Chemical group 0.000 claims 29
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 28
- 125000001072 heteroaryl group Chemical group 0.000 claims 21
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 18
- 229910052757 nitrogen Inorganic materials 0.000 claims 18
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 15
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 15
- 229910052736 halogen Inorganic materials 0.000 claims 15
- 150000002367 halogens Chemical class 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 15
- 150000004677 hydrates Chemical class 0.000 claims 14
- 239000012453 solvate Substances 0.000 claims 14
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 12
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 10
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 10
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 9
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 8
- 125000003003 spiro group Chemical group 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 239000011593 sulfur Substances 0.000 claims 6
- 206010006451 bronchitis Diseases 0.000 claims 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 5
- 229910052801 chlorine Inorganic materials 0.000 claims 5
- 229910052731 fluorine Inorganic materials 0.000 claims 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 5
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000001301 oxygen Substances 0.000 claims 4
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims 4
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 3
- 206010035664 Pneumonia Diseases 0.000 claims 3
- 230000000172 allergic effect Effects 0.000 claims 3
- 229910052794 bromium Inorganic materials 0.000 claims 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims 2
- ONQBOTKLCMXPOF-UHFFFAOYSA-N 1-ethylpyrrolidine Chemical compound CCN1CCCC1 ONQBOTKLCMXPOF-UHFFFAOYSA-N 0.000 claims 2
- 206010001889 Alveolitis Diseases 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 150000001721 carbon Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 229910021386 carbon form Inorganic materials 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 235000017168 chlorine Nutrition 0.000 claims 2
- 125000001309 chloro group Chemical class Cl* 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 2
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 2
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 2
- 230000000144 pharmacologic effect Effects 0.000 claims 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims 1
- JOMNTHCQHJPVAZ-UHFFFAOYSA-N 2-methylpiperazine Chemical compound CC1CNCCN1 JOMNTHCQHJPVAZ-UHFFFAOYSA-N 0.000 claims 1
- 206010052613 Allergic bronchitis Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009137 Chronic sinusitis Diseases 0.000 claims 1
- 208000027932 Collagen disease Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 208000000592 Nasal Polyps Diseases 0.000 claims 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims 1
- 206010037423 Pulmonary oedema Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 230000007883 bronchodilation Effects 0.000 claims 1
- 208000029771 childhood onset asthma Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 244000000013 helminth Species 0.000 claims 1
- 230000036571 hydration Effects 0.000 claims 1
- 238000006703 hydration reaction Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000016366 nasal cavity polyp Diseases 0.000 claims 1
- 208000037916 non-allergic rhinitis Diseases 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims 1
- 208000005333 pulmonary edema Diseases 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 0 CC(C*(C)c1c(C2*C(C)C(C)(*3)c4c5cccc4)[s]c(*)n1)C2C(*)C35*#I Chemical compound CC(C*(C)c1c(C2*C(C)C(C)(*3)c4c5cccc4)[s]c(*)n1)C2C(*)C35*#I 0.000 description 2
- UQFQONCQIQEYPJ-UHFFFAOYSA-N C[n]1nccc1 Chemical compound C[n]1nccc1 UQFQONCQIQEYPJ-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N Cc1ncccc1 Chemical compound Cc1ncccc1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004048877A DE102004048877A1 (de) | 2004-10-07 | 2004-10-07 | PI3-Kinasen |
| DE102004048877.0 | 2004-10-07 | ||
| DE102005005813A DE102005005813A1 (de) | 2005-02-09 | 2005-02-09 | PI3-Kinasen |
| DE102005005813.2 | 2005-02-09 | ||
| PCT/EP2005/055015 WO2006040279A1 (de) | 2004-10-07 | 2005-10-05 | Pi3-kinasen |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008515852A JP2008515852A (ja) | 2008-05-15 |
| JP2008515852A5 true JP2008515852A5 (enExample) | 2008-11-27 |
| JP5122287B2 JP5122287B2 (ja) | 2013-01-16 |
Family
ID=35583390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007535159A Expired - Lifetime JP5122287B2 (ja) | 2004-10-07 | 2005-10-05 | Ｐｉ３キナーゼ |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US7691888B2 (enExample) |
| EP (2) | EP1802636B1 (enExample) |
| JP (1) | JP5122287B2 (enExample) |
| KR (1) | KR20070064660A (enExample) |
| CN (1) | CN101048418A (enExample) |
| AR (1) | AR055273A1 (enExample) |
| AU (1) | AU2005293607A1 (enExample) |
| BR (1) | BRPI0516557A (enExample) |
| CA (1) | CA2579279C (enExample) |
| IL (1) | IL182398A0 (enExample) |
| MX (1) | MX2007004051A (enExample) |
| RU (2) | RU2403258C2 (enExample) |
| TW (1) | TW200628475A (enExample) |
| WO (1) | WO2006040279A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050096332A1 (en) * | 2003-10-30 | 2005-05-05 | Boehringer Ingelheim International Gmbh | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes |
| AU2005293607A1 (en) * | 2004-10-07 | 2006-04-20 | Boehringer Ingelheim International Gmbh | PI3 kinases |
| US7691868B2 (en) | 2006-04-06 | 2010-04-06 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydro-quinazoline |
| US20070238746A1 (en) * | 2006-04-06 | 2007-10-11 | Trixi Brandl | Thiazolyl-dihydro-chinazoline |
| US20070238718A1 (en) * | 2006-04-06 | 2007-10-11 | Matthias Grauert | Thiazolyl-dihydro-indazole |
| MX2008012535A (es) * | 2006-04-06 | 2008-10-10 | Boehringer Ingelheim Int | Tiazolil-dihidro-indazoles. |
| US7517995B2 (en) * | 2006-04-06 | 2009-04-14 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydro-cyclopentapyrazole |
| US20070259855A1 (en) * | 2006-04-06 | 2007-11-08 | Udo Maier | Thiazolyl-dihydro-indazole |
| DE602006002385D1 (de) * | 2006-06-26 | 2008-10-02 | Helm Ag | Verfahren zur Herstellung von Pramipexole |
| EP2045253A4 (en) * | 2006-06-29 | 2013-01-23 | Nissan Chemical Ind Ltd | alpha-amino acid derivative and pharmaceutical agent containing it as an active ingredient |
| US8779154B2 (en) | 2006-09-26 | 2014-07-15 | Qinglin Che | Fused ring compounds for inflammation and immune-related uses |
| GB0619611D0 (en) * | 2006-10-04 | 2006-11-15 | Ark Therapeutics Ltd | Compounds and their use |
| WO2009039140A1 (en) * | 2007-09-17 | 2009-03-26 | Smithkline Beecham Corporation | Pyridopyrimidine derivatives as pi3 kinase inhibitors |
| US20110052643A1 (en) * | 2008-01-07 | 2011-03-03 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| PE20091617A1 (es) * | 2008-03-13 | 2009-11-12 | Boehringer Ingelheim Int | Tiazolil-dihidro-indazoles |
| WO2009120826A1 (en) * | 2008-03-27 | 2009-10-01 | Wyeth | 2-aryl- and 2-heteroarylthiazolyl compounds, methods for their preparation and use thereof |
| RU2506267C2 (ru) | 2008-03-31 | 2014-02-10 | Дженентек, Инк. | Бензопирановые и бензоксепиновые ингибиторы рi3k и их применение |
| WO2010007943A1 (ja) * | 2008-07-17 | 2010-01-21 | 旭化成ファーマ株式会社 | 含窒素複素環化合物 |
| US20110230472A1 (en) * | 2008-08-29 | 2011-09-22 | Shionogi & Co., Ltd. | Ring-fused azole derivative having pi3k-inhibiting activity |
| EP2350084B1 (en) * | 2008-10-17 | 2015-06-24 | Boehringer Ingelheim International GmbH | Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (pi3-kinases) inhibitor |
| GB0900404D0 (en) | 2009-01-12 | 2009-02-11 | Addex Pharmaceuticals Sa | New compounds 4 |
| US8278302B2 (en) | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| EP2421872B1 (en) * | 2009-04-22 | 2015-06-10 | Boehringer Ingelheim International GmbH | Thia-triaza-as-indacenes as pi3-kinases inhibitors for the treatment of cancer |
| US8288379B2 (en) | 2009-04-22 | 2012-10-16 | Boehringer Ingelheim International Gmbh | Thia-triaza-cyclopentazulenes |
| ES2432671T3 (es) * | 2009-07-02 | 2013-12-04 | Novartis Ag | 2-carboxamida cicloamino ureas útiles como inhibidores de PI3K |
| UA111579C2 (uk) | 2009-08-17 | 2016-05-25 | Інтеллікіне Ллк | ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ |
| EP2483277B1 (en) * | 2009-09-28 | 2015-12-02 | F. Hoffmann-La Roche AG | Benzoxepin pi3k inhibitor compounds and methods of use |
| EP2845592A1 (en) * | 2009-09-28 | 2015-03-11 | F. Hoffmann-La Roche AG | Benzoxazepin PI3K inhibitor compounds and methods of use |
| CN102695710B (zh) * | 2009-11-13 | 2015-08-19 | 默克雪兰诺有限公司 | 三环吡唑胺衍生物 |
| CN103153062B (zh) | 2010-05-24 | 2015-07-15 | 因特利凯有限责任公司 | 杂环化合物及其用途 |
| US20130252944A1 (en) * | 2010-07-14 | 2013-09-26 | Christelle Bolea | Novel fused pyrazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
| GB201011831D0 (en) | 2010-07-14 | 2010-09-01 | Addex Pharmaceuticals Sa | New compounds 5 |
| TW201245176A (en) | 2011-01-26 | 2012-11-16 | Boehringer Ingelheim Int | New 5-alkynyl-pyridines |
| EP2546249A1 (en) | 2011-07-15 | 2013-01-16 | Boehringer Ingelheim International Gmbh | 5-Alkynyl-pyridines |
| US8466162B2 (en) | 2011-01-26 | 2013-06-18 | Boehringer Ingelheim International Gmbh | 5-alkynyl-pyridines |
| TWI592411B (zh) | 2011-02-23 | 2017-07-21 | 英特爾立秦有限責任公司 | 激酶抑制劑之組合及其用途 |
| EP2678016B1 (en) | 2011-02-23 | 2016-08-10 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
| RU2013143747A (ru) | 2011-03-21 | 2015-04-27 | Ф. Хоффманн-Ля Рош Аг | Соединения бензоксазепина, селективные в отношении pi3k p110 дельта и способы их применения |
| CA2861496A1 (en) * | 2012-02-06 | 2013-08-15 | Glaxosmithkline Intellectual Property (No.2) Limited | Pi3k inhibitors for treating cough |
| WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
| JP7768505B2 (ja) | 2018-06-01 | 2025-11-12 | コーネル・ユニバーシティー | Ｐｉ３ｋに関連する疾患または障害に対する併用療法 |
| US11174263B2 (en) | 2018-12-31 | 2021-11-16 | Biomea Fusion, Inc. | Inhibitors of menin-MLL interaction |
| AU2019417833B2 (en) | 2018-12-31 | 2024-11-07 | Biomea Fusion, Inc. | Irreversible inhibitors of menin-MLL interaction |
| CA3228627A1 (en) | 2021-08-11 | 2023-02-16 | Thomas Butler | Covalent inhibitors of menin-mll interaction for diabetes mellitus |
| EP4387972A1 (en) | 2021-08-20 | 2024-06-26 | Biomea Fusion, Inc. | Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer |
| WO2024155710A1 (en) | 2023-01-18 | 2024-07-25 | Biomea Fusion, Inc. | Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6- yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2-pyridinecarboxamide as a covalent inhibitor of menin-mll interaction |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5533405A (en) | 1978-08-29 | 1980-03-08 | Teijin Ltd | Hexahydronaphtho(1',2':4,5)imidazo(2,1-b)thiazole and its preparation |
| WO1979001080A1 (fr) | 1978-05-17 | 1979-12-13 | Teijin Ltd | Hexahydronaphtoimidazothiazoles et procede pour leur preparation |
| ATE45735T1 (de) * | 1984-12-22 | 1989-09-15 | Thomae Gmbh Dr K | Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arnzneimittel. |
| US5358949A (en) * | 1986-03-05 | 1994-10-25 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives |
| US5182290A (en) * | 1991-08-27 | 1993-01-26 | Neurogen Corporation | Certain oxazoloquinolinones; a new class of GABA brain receptor ligands |
| TW260664B (enExample) * | 1993-02-15 | 1995-10-21 | Otsuka Pharma Factory Inc | |
| JP3670309B2 (ja) | 1993-04-01 | 2005-07-13 | 第一製薬株式会社 | 二環性複素環化合物 |
| NO941135L (no) | 1993-04-01 | 1994-10-03 | Daiichi Seiyaku Co | Tiazolpyrimidin derivater |
| TW420669B (en) * | 1994-03-28 | 2001-02-01 | Nissan Chemical Ind Ltd | Pyridine type thiazolidines |
| AU727654B2 (en) * | 1997-06-13 | 2000-12-21 | Yamanouchi Pharmaceutical Co., Ltd. | Tricyclic pyrazole derivative |
| US7091227B2 (en) * | 2000-02-07 | 2006-08-15 | Abbott Gmbh & Co. Kg | Benzothiazole derivatives |
| HUP0300382A3 (en) * | 2000-03-29 | 2006-11-28 | Cyclacel Ltd | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders and pharmaceutical compositions containing the compounds |
| US6608053B2 (en) * | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| KR100423899B1 (ko) * | 2000-05-10 | 2004-03-24 | 주식회사 엘지생명과학 | 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸 |
| US6908932B2 (en) | 2001-10-24 | 2005-06-21 | Iconix Pharmaceuticals, Inc. | Modulators of phosphoinositide 3-kinase |
| MY156407A (en) * | 2002-02-28 | 2016-02-26 | Novartis Ag | 5-phenylthiazole derivatives and use as p13 kinase inhibitors |
| EP1349179A1 (en) * | 2002-03-18 | 2003-10-01 | ATOFINA Research | Conductive polyolefins with good mechanical properties |
| CA2493843C (en) | 2002-07-10 | 2012-04-17 | Applied Research Systems Ars Holding N.V. | Azolidinone-vinyl fused-benzene derivatives |
| ATE411996T1 (de) | 2002-09-30 | 2008-11-15 | Bayer Healthcare Ag | Kondensierte azolpyrimidinderivate |
| JP2006510661A (ja) | 2002-12-06 | 2006-03-30 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | Ｐｉ３ｋの阻害剤としてのベンズオキサジン−３−オン類及びその誘導体 |
| WO2004056820A1 (en) | 2002-12-20 | 2004-07-08 | Warner-Lambert Company Llc | Benzoxazines and derivatives thereof as inhibitors of pi3ks |
| GB0315966D0 (en) * | 2003-07-08 | 2003-08-13 | Cyclacel Ltd | Compounds |
| NO20041733L (no) * | 2004-04-28 | 2005-10-31 | Thin Film Electronics Asa | Organisk elektronisk krets med funksjonelt mellomsjikt og fremgangsmate til dens fremstilling. |
| AU2005293607A1 (en) * | 2004-10-07 | 2006-04-20 | Boehringer Ingelheim International Gmbh | PI3 kinases |
| FR2887993B1 (fr) * | 2005-07-01 | 2007-08-03 | Commissariat Energie Atomique | Dispositif de detection de rayonnements a electrodes empilees et methode de detection de rayonnements ionisants mettant en oeuvre un tel dispositif |
| US20070259855A1 (en) * | 2006-04-06 | 2007-11-08 | Udo Maier | Thiazolyl-dihydro-indazole |
| BRPI0710841A2 (pt) * | 2006-04-06 | 2011-08-23 | Boehringer Ingelheim Int | compostos derivados de tiazolil dihidroindazóis como inibidores da proteìna quinase, preparações farmacêuticas e o uso das mesmas |
-
2005
- 2005-10-05 AU AU2005293607A patent/AU2005293607A1/en not_active Abandoned
- 2005-10-05 RU RU2007116858/04A patent/RU2403258C2/ru not_active IP Right Cessation
- 2005-10-05 RU RU2007116861/04A patent/RU2007116861A/ru not_active Application Discontinuation
- 2005-10-05 EP EP05805652A patent/EP1802636B1/de not_active Expired - Lifetime
- 2005-10-05 EP EP11158787A patent/EP2343303A1/de not_active Withdrawn
- 2005-10-05 KR KR1020077010387A patent/KR20070064660A/ko not_active Withdrawn
- 2005-10-05 WO PCT/EP2005/055015 patent/WO2006040279A1/de not_active Ceased
- 2005-10-05 US US11/243,796 patent/US7691888B2/en not_active Expired - Lifetime
- 2005-10-05 BR BRPI0516557-1A patent/BRPI0516557A/pt not_active IP Right Cessation
- 2005-10-05 MX MX2007004051A patent/MX2007004051A/es not_active Application Discontinuation
- 2005-10-05 CN CNA2005800344060A patent/CN101048418A/zh active Pending
- 2005-10-05 CA CA2579279A patent/CA2579279C/en not_active Expired - Lifetime
- 2005-10-05 JP JP2007535159A patent/JP5122287B2/ja not_active Expired - Lifetime
- 2005-10-05 US US11/244,299 patent/US20060106013A1/en not_active Abandoned
- 2005-10-06 TW TW094134899A patent/TW200628475A/zh unknown
- 2005-10-07 AR ARP050104225A patent/AR055273A1/es unknown
-
2007
- 2007-04-10 IL IL182398A patent/IL182398A0/en unknown
-
2009
- 2009-02-05 US US12/366,248 patent/US8232286B2/en active Active
-
2010
- 2010-01-11 US US12/685,213 patent/US8207349B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008515852A5 (enExample) | ||
| RU2007116861A (ru) | P13-киназы | |
| JP2009532417A5 (enExample) | ||
| JP2009539848A5 (enExample) | ||
| JP2009534405A5 (enExample) | ||
| JP2008510828A5 (enExample) | ||
| JP2006151984A5 (enExample) | ||
| JP2010090138A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| JP2009534403A5 (enExample) | ||
| JP2009529540A5 (enExample) | ||
| JP2010513447A5 (enExample) | ||
| JP2005519932A5 (enExample) | ||
| JP2015535832A5 (enExample) | ||
| JP2011520815A5 (enExample) | ||
| JP2008510762A5 (enExample) | ||
| JP2010501478A5 (enExample) | ||
| JP2015526453A5 (enExample) | ||
| JP2009534407A5 (enExample) | ||
| JP2010540593A5 (enExample) | ||
| RU2008129620A (ru) | Пиразиноилгуанидиновые соединения, применяемые в лечении воспалительных или аллергических заболеваний | |
| JP2009536221A5 (enExample) | ||
| JP2016532677A5 (enExample) | ||
| JP2009532413A5 (enExample) | ||
| JP2008516968A5 (enExample) |